Objectives: To investigate unwarranted variation in ventilation tube insertions for otitis media with effusion in children in England. This procedure is known to be 'overused' from clinical audits, as only one in three ventilation tube insertions conforms to the appropriateness criteria of the National Institute for Health and Care Excellence (NICE); but audits cannot identify the scale of 'underuse' -i.e. patients who would benefit but are not treated. Methods: To explore both 'underuse' and 'overuse' of ventilation tubes for otitis media with effusion, we developed an epidemiological model based on: definitions of children with otitis media with effusion expected to benefit from ventilation tubes according to NICE guidance; epidemiological and clinical information from a systematic review; and expert judgement. A range of estimates was derived using Monte Carlo simulation and compared with the number of ventilation tubes provided in the English National Health Service in 2010. Results: About 32,200 children in England would be expected to benefit from ventilation tubes for otitis media with effusion per year (between 20,411 and 45,231 with 90% certainty). The observed number of ventilation tubes for otitis media with effusion-associated diagnoses was 16,824. Conclusions: The expected population capacity to benefit from ventilation tubes for otitis media with effusion based on NICE guidance appeared to exceed, by far, the number of ventilation tubes provided in the English National Health Service. So, while there is known 'overuse', there also may be substantial 'underuse' of ventilation tubes for otitis media with effusion if NICE criteria were applied. Future investigations of unwarranted variation should, therefore, not only focus on the patients who are treated but also consider the potential for benefit at the population level.
Introduction
Systems of health care in countries that are under severe fiscal pressures 1 seek to do more for less: to increase the benefits from health care and reduce its costs. There is evidence of large and persistent variations in medical practice across small areas, which have been documented in various countries. 2 This evidence is generally seen as an indication of 'overuse'; i.e. where reductions in rates of treatment could release resources with gains in health. 3 In England's National Health Service (NHS), commissioners are allocated budgets for their populations and have to develop policies for services for which they are and are not prepared to pay. One such policy seeks to reduce unwarranted variation by restricting access to procedures listed as being of 'low clinical value'. 4 However, due to the lack of an objective reference point against which to evaluate 'overuse' (ineffective care that is more likely to harm than help the patient 5 ) or 'underuse' (the failure to provide services from which the patient would likely benefit 5 ), information on variations remains essentially ambiguous. 6 The purpose of this article is to investigate unwarranted variations by modelling the scale of 'underuse' or 'overuse' of ventilation tubes (VTs; grommets) for children with otitis media with effusion (OME) in England.
VT insertions are a classic case of high geographic variation. Variations in England have been documented since the 1980s 7 and have persisted: in 2010/ 2011, there was about eight-fold variation across 151 commissioners (with a mean population of about 300,000). 8 VTs have been listed by commissioners as a 'low value' procedure, 4 seeking to restrict referrals by general practitioners (GPs). Despite that, VT insertions remain one of the most frequent surgical interventions in children with over 32,000 insertions in 2010/2011, of which 23,500 were among children younger than 14 years. 9 Clinical audits in the US 10 and the UK, 11 using different criteria of appropriateness, found that only one in three VT insertions was appropriate, suggesting substantial 'overuse'. However, audits of care delivered cannot address the scale of 'underuse' of VTs for OME. We, therefore, developed an epidemiological model to estimate the number of children with capacity to benefit from VTs for OME, if National Institute for Health and Care Excellence (NICE) guidance 12 were being followed, and compared this with the number of VTs actually provided in England.
Methods
Recommended clinical pathway OME is defined as an effusion in the middle ear cleft, in the absence of signs of acute inflammation. It may cause conductive hearing loss, which, if persistent, can affect speech and language development, educational performance and behaviour. 13 By the age of four years, about 80% of children have had episodes of OME. 14 As OME is transitory for most children, the NICE clinical pathway used in the model (Figure 1 ) recommends an initial period of active observation over three months and repeat audiological testing at the end of this period. At that stage, it is recommended that VTs are offered for children younger than 12 years who meet three 'core' criteria: (1) bilateral OME with (2) a hearing level in the better hearing ear of 25 to 30 dBHL or higher that (3) is documented over a period of three months. The crucial point is that NICE guidance does not define VTs as an intrinsically 'low value' procedure, but recognizes their value in relation to a set of evidence-based criteria. In exceptional cases, VTs may also be offered if clinicians judge the impact of OME-related hearing impairment on the child's development, wellbeing or social functioning to be substantial. 12
Modelling assumptions
Based on the NICE criteria, our epidemiological model to estimate population capacity to benefit from VTs for OME is formulated below. The modelling assumptions are summarized in Table 1 . The parameters, their definition and estimation are given in Table 2 .
(1) Incidence: The number of new cases of OME in any given year, N(OME), is determined by the annual age-specific cumulative incidence (risk) I j of OME multiplied by the susceptible population in a given age group S j , summed over all eligible age groups j. The subgroup of cases with bilateral OME and a hearing level at NICE threshold level is expressed by
(2) Disease process: We model the probability of OME persisting at time t from the onset of OME as an exponential process (adapted from Zielhuis et al. 15 ) of the form
(3) Capacity to benefit from VTs for OME: As OME is transitory, the population with capacity to benefit will diminish as time passes since the onset of OME. Population capacity to benefit from VTs for OME is estimated as
Data sources and extraction
To estimate parameter values, we carried out a systematic literature review according to PRISMA guidelines 16 (see online Appendix A for details of the search strategy and data extraction, and online Appendix B for the rationale for the study inclusion criteria).
Setting and population
The setting is the NHS in England. The population includes children younger than 12 years covered by NICE guidance. However, we were unable to find incidence studies that met our inclusion criteria for the age groups 0, 1, 4 and 9 to 12 years. We focused the analysis on children aged 2 to 8 years (extrapolating the incidence for four-year olds from three-year olds) which is the age group with the majority of VT insertions (0 to 12 years: 19,805; 2 to 8 years: 16,824 procedures with OME-associated diagnoses in 2010/2011 9 ). To estimate the susceptible population, the total population of children has been corrected for an estimate of OME prevalence (online Appendix C). We focused on children meeting the three NICE 'core' criteria for VT insertion. The number of exceptional cases, which are identified through clinical judgement, was not modelled. This means that our estimates are probably conservative and underestimate the number of children with capacity to benefit from VTs.
Model validation
All modelling assumptions were iteratively refined in consultation with the Project Steering Group. During an expert workshop in September 2012, 10 participants with complementary expertise in audiology, ear, nose and throat disorders, general practice and epidemiology were invited to examine the model's overall structure and individual components. The group judged the model to be a fair representation of the NICE care pathway and of the disease process governing OME given the existing evidence.
Sensitivity analysis
Data retrieved from the literature raised the issue of potential for bias in terms of internal validity (the extent to which the design of original studies ensured accurate measurement of the parameters of interest) and external validity (the extent to which studies conducted were applicable to the present English context). We judged that the different sources of uncertainty in the evidence would merit supplementing this with expert judgement. We followed a structured approach to expert elicitation. 17 We provided the panel of experts with the literature-based estimates, encouraged discussion and elicited fractiles of subjective probability distributions. We then used these estimates in a Monte Carlo simulation performed in @RISK 5.0 to gain an insight into the impact of the combined uncertainty in parameter estimates on the modelling results. 18 (1) The model starts with a population of children at risk of developing OME.
(2) Of these children, some will develop bilateral OME with a hearing level of þ25 dBHL. (3) The recovery rate determines the proportion of children recovering and 'returning' to the susceptible population. The remaining (persistent) cases present in primary care. (4) Children who are referred to specialist care undergo formal assessment and diagnosis. (5) Patients for whom a diagnosis of OME is confirmed after three months 'watchful waiting' have a capacity to benefit from VTs for OME and should be considered for surgical intervention according to NICE guidance. Boxes represent mutually exclusive, collectively exhaustive states in which parts of the population of children find themselves. Arrows represent the transition probabilities (incidence and recovery rates) and the waiting time that link the states. 
Assumption
Comment a 1 Exponential disease process For the population level an exponential and rate-constant recovery process is applied based on Zielhuis et al. 1 The authors found a good fit (r 2 ¼ 0.98) between the exponential model estimated with Kaplan-Meier technique and the empirical data from a prospective cohort study (n ¼ 816 children with valid measurements). For a discussion of the epidemiological models for representing the natural course of OME see. 2 However, this may mask the few children suffering from highly persistent OME. At the individual level, OME may also be more episodic. 2 Stationary population Assumes a stable age distribution within each age group and year (based on mid-year population estimates). 3 t Total waiting time t represents a parameter that reflects demand-and supply-side aspects of patient utilization behaviour, access and referral policies and the organization of care delivery. Is varied over a range to account for uncertainy in three distinct sub-intervals: t 1 , time to presentation in primary care: Seeks to account for the time lag for detecting hearing loss associated with OME. As OME is an often asymptomatic or 'silent' condition, conductive hearing loss is likely to be noted by parents, teachers or carers only after some time (if at all). t 2 , time from presentation in primary care to diagnosis in specialist care: According to the NHS Constitution, patients have a right to be seen by a consultant within maximum 18 weeks after referral. 3 This is a political rather than clinical standard. It also refers to maximum not to optimum waiting times. National HES data confirm a median waiting time of 7.3 weeks (51 days) for grommets 4 from the decision to admit to actual admission (excluding days of deferment and suspension). t 3 , time from diagnosis to confirmation: supposed to be three months according to NICE guidance. 4
Incidence is represented as a function of age
Age-based incidence rates are used as the association of OME with age is well-established and most reliably documented. 5 5 Incidence rates are at a population level and include both first and recurrent cases About 50% of children recovering from OME experience a further episode of OME. 1, 6 However, due to the often asymptomatic character of OME, even robust incidence studies cannot rule out the possibility that a child has previously suffered from OME. Modelling history of OME could thus lead to an overestimation of cases. Therefore, incidence rates used in the model do not differentiate between first-time and recurrent cases and are assumed to include both. 6 Incident cases Potential underestimation of transient cases occuring and recovering between the screening intervals of three months 7 or four months. 8 However, OME is considered a disease occuring only after several weeks of middle ear pathology. 2 7 Seasonal variation in incidence is averaged out over one year.
The incidence of OME is known to be higher in winter; however, the incidence data used in the model and the model output represent an annual average. 8
Fixed proportion of bilateral OME.
Reflects the nature of the data that has been collected at (discrete) screening time points; although at individual level, children may switch between unilateral and bilateral states. Results Figure 2 illustrates the combined uncertainty in the expected incidence of bilateral OME with a hearing level of þ25 dB. Based on 10,000 iterations of the model and given the set of input distributions, the resulting distribution of the expected incidence ranges between 63,800 and 143,600 cases per year in England with 90% certainty (mean estimate: 102,083 cases).
These results from the Monte Carlo simulation are used to model the expected number of children with capacity to benefit from VTs for OME as the total waiting time from the onset of OME is varied over a range.
Since OME is transitory, the expected population capacity to benefit from VTs for OME depends on the total waiting time from the onset of OME to the point where treatment is considered (Figure 3) . NICE guidance recommends a three-month period of active observation following the first formal diagnosis. Thus, if we assume that the first outpatient appointment takes place immediately after the onset of OME, then the mean estimate of children for whom VTs would be clinically indicated would be approximately 51,000 (at t¼three months; between 32,400 and 71,800 with 90% certainty). There is currently no national guidance on the recommended waiting time from the onset of OME until the first outpatient appointment (waiting time References are given in online Appendix D.
intervals t 1 and t 2 in Figure 1 ). Since our model aims to provide a benchmark of expected care, rather than a reflection of actual practice, our assumptions about the length of these intervals ( Table 2) represent clinically 'ideal' circumstances based on expert group consensus. Assuming a one-month buffer period before parents become concerned about the symptoms of OME and visit a GP and another month before children have their first outpatient appointment, we would expect approximately 32,200 children to benefit from VTs for OME (at t ¼ five months; 90% certainty interval 20,411 to 45,231). This contrasts with 16,824 VTs that were provided for OME-associated diagnosis codes in the age group 2 to 8 years in 2010/11 in England. As can be seen in Table 3 , even if we were to assume coding inaccuracies in VTs coded with OME-associated diagnoses, the conclusions would be unaffected.
Discussion
This study shows that the expected capacity to benefit from VTs for OME among children in England, according to NICE guidance, exceeds the number of VTs that were provided in the NHS. Our model hence reveals the possibility of 'underuse' of VTs for OME at the national level. However, the findings also Figure 3 . Expected number of children with capacity to benefit from VTs for OME depending on total waiting time in England (reference year 2010, age groups 2 to 8 years). Given different starting estimates of the total annual incidence of bilateral OME with hearing level of þ25dB for the age groups 2 to 8 from the Monte Carlo simulation (Figure 2 ) of approximately 102,083 cases (mean estimate); 63,800 cases (lower 5% bound); and 143,600 cases (upper 95% bound). Figure 2 . Monte Carlo simulation of expected annual incidence of bilateral OME with a hearing level of þ25 dB in England (reference year 2010, age groups 2 to 8 years). x-axis: expected annual incidence of bilateral OME with þ25 dBHL in England (2010). y-axis: frequency of observing a particular output value based on 10,000 iterations of the simulation model.
need to be interpreted in the light of the roughly eightfold variation in treatment rates between commissioners in England, 8 which suggests that 'overuse' might still occur in some areas.
Strengths and weaknesses of the study
The model draws on evidence-based clinical guidance to obtain an indicative estimate of the scale of potential 'underuse' or 'overuse' of VTs in a given population. This estimate does not represent the 'right (treatment) rate', which should also depend on informed patient choice. It attempts to approximate the level of treatment that the NHS would be expected to offer to patients, if NICE criteria were accepted as a valid basis for identifying all patients with capacity to benefit from VTs. We recognize that NICE criteria can only be approximate predictors of 'benefit' from VTs for hearing outcomes, especially for cases located just above or below the þ25 dBHL threshold, with even more uncertainty over the impact of VTs on childhood development and the child's quality of life. Thus, from a normative standpoint, our model can only give an approximate estimate of how many VTs should be offered, which may change once better predictors of benefit become available. The model uses best available evidence identified through a systematic review. The shortage of high-quality studies meeting our inclusion criteria did not allow for a meta-analysis, and we have demonstrated the consequent uncertainty in our parameter estimates and their combined impact on the modelling results by Monte Carlo simulation. The observed number of VTs provided covers patients treated in the NHS; unfortunately, we were unable to obtain estimates of the scale of private practice in England. However, total private sector expenditure on health care in the UK (2011) is 17.2%, 19 which would not substantially affect the conclusions of our study.
Findings in relation to studies of utilization
Our study, using a population model, complements utilization-based studies of treatment appropriateness. A recent multi-centre study in England found that only 32.2% of VTs inserted complied with the three 'core' NICE criteria, while 54.8% of VTs were provided on the basis of 'exceptional circumstances'. 11 Although NICE guidelines also explicitly encourage the provision of VTs beyond the three 'core' criteria if clinicians judge the impact of OME on the child's development and social functioning to be substantial, 12 the apparent reframing of 'exceptions' under clinical guidance as the 'rule' in clinical practice does raise questions over treatment appropriateness. This study adds to these findings by illustrating that, while there may be deviation from NICE 'core' criteria, which could either reflect patient-oriented treatment or 'overuse' of VTs, 'unmet clinical need' according to these 'core' criteria may be present simultaneously.
Policy implications
An increasingly common policy among health care commissioners in England 4 is to label VTs per se as 'overused' and 'low value', and hence restrict access. Our findings highlight the possibility of substantial 'underuse' among children in England for whom VTs are deemed beneficial and thus call for a more nuanced policy response. Because there is no evidence of a systematic relationship between high rates of utilization and high rates of inappropriateness, 20 we need a policy that tackles overuse by clinical audit of treatment, and ensures access to effective care for children suffering from persistent bilateral OME with a degree of hearing loss that is disabling and may affect their health and development. This policy would use the ideas of epidemiological surveillance of medical care 21 to enlarge the framing of clinical appropriateness from audits of services delivered to population capacity to benefit. Understanding the number of people who might be expected to benefit, given local population characteristics and clinical guidance, has relevance also for other high-volume services such as cataract surgery, joint arthroplasty or spinal procedures: it could help widen clinical concerns from individual patients towards the entire population who could (not) benefit and should hence (not) be offered a procedure. This policy would require investments in: recommended intervention criteria that are more directly related to patient benefit, based on evidence from everyday practice (high-quality clinical databases rather than randomized controlled trials) on the realworld impacts of surgery on health outcomes compared to a control group; and good information on disease epidemiology.
Implications for research and quality improvement
To explain the discrepancy between 'observed' VT provision and the 'expected' number of VTs offered, a multi-faceted qualitative and quantitative approach involving commissioners, professionals and families is needed to identify barriers along the whole care pathway and then design interventions for improvement. As parents, teachers and nurseries may fail to recognize hearing loss associated with OME, 22 it is possible that many patients do not present to primary care in the first place. GPs, school nurses and health visitors need the knowledge and capacity to identify patients with suspected OME and ensure timely referral and diagnosis according to NICE criteria; in a recent UK-based study, participating GPs correctly identified OME in only 53% of cases, which is not much higher than chance. 23 Since VTs feature widely as a 'low value' procedure, 4 GPs might also tend to withhold referrals even for patients for whom VTs could be a clinically and cost-effective option. Delays in care and a long history of 'watchful waiting' in community services may thus, in practice, exceed the two-month interval from the onset of OME to formal diagnosis which we assumed as a clinically 'ideal' benchmark in our model. To overcome fragmentation, GPs, audiologists and ENT specialists need to work together to ensure early recognition and referral of children with capacity to benefit from treatment. Patients and carers deliberately choosing non-surgical treatment alternatives, such as hearing aids or medical management, may also, in part, explain the apparent discrepancy between 'expected' and 'observed' treatment rates. However, many patients and carers may not be given the opportunity to discuss and understand their options for treatment, resulting in uninformed use of other care. Future research might therefore also examine regional variations in patient preferences and approaches to shared decision making, 24 and how these add to, or interact with, differences in local commissioning criteria and socioeconomic inequalities.
Conclusions
This study has highlighted the case of VTs for OME which, although known to be 'overused' based on audits of care provided, simultaneously seems to exhibit substantial 'underuse' at a population level in England based on NICE guidance. Because 'overuse' and 'underuse' may coexist as sources of unwarranted variation, clinicians and managers should examine if all children who would be expected to benefit from VTs for OME also have access to the procedure.
The study is of one condition in England, but raises an important general issue in using studies of medical practice variations to inform policies to reduce 'overuse' and thus release resources to meet rising demand in times of austerity. To maximize benefits for patients within resource constraints, policies where medical practice varies ought to tackle 'overuse' by auditing care that is provided, and 'underuse' by assessing capacity to benefit in populations.
